Cramer said this biotech reminded him of a big pharma company during the sector's heyday in the 1990's.
Looking for company that's growing fast and has a deep pipeline? Cramer is too.
Stocks ended near session highs in choppy trading, with the S&P 500 finishing in positive territory for the first Monday in 2013 and the Dow close to hitting its record closing high, as investors shook off earlier worries over China and a lack of progress over the sequester.
U.S. stock index futures were lower Monday amid concerns about the U.S.'s unresolved "sequester" and the introduction of harsher-than-expected property curbs in China.
Some of the names on the move ahead of the open.
These four biotech stocks could take a big hit when investors start to focus on lower-valued stocks in other industries. TheStreet.com reports.
Morgan Stanley has identified some 40 stocks that could be candidates for tender offers in the next 12 months using its new quantitative model.
A flood of earnings reports, including major technology and industrial companies, could make or break the stock market’s surprise January rally in the week ahead.
Ready for the downpour? Earnings season kicks into high gear in the week ahead. Fortunately, Cramer has a game plan.
According to Cramer a shift is underway. You’d best position for it now.
Find out what Wall Street analysts had to say about Boeing, Apple, Yum Brands and Tiffany in this CNBC.com Stock Blog Roundup.
Jim Cramer’s researcher Nicole Urken reviews the potential biotech pipeline winners there were highlighted this week on Mad Money.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
Take a look at some of Monday's midday movers:
This could be the most difficult earnings season in years, revealed "Mad Money" host Jim Cramer. Here’s what’s on his radar.
TheStreet.com offers up 13 biotech predictions for 2013.
TheStreet.com details the 10 best-performing biopharmaceutical stocks of 2012 and their outlook for 2013.
Oct 25- Celgene Corp's quarterly earnings rose 14 percent, beating expectations on strong sales of its Revlimid cancer treatment and lower costs, but investors were more focused on ongoing studies of its promising new medicines and wider uses for Revlimid.
*3rd- quarter EPS $1.91 excluding items vs Street view $1.60. ``They put up a nice solid quarter,'' said RBC Capital Markets analyst Michael Yee. ``What's being appreciated in biotech is the consistent beat and raise by all four of the large cap biotechs this week and that's got the sector on the move.''.
*Q3 EPS, excluding items, $1.29, vs. Oct 25- Celgene Corp's quarterly earnings rose 14 percent, beating expectations on strong sales of its Revlimid cancer treatment and lower costs, but investors were more focused on ongoing studies of its promising new medicines and wider uses for Revlimid. Excluding special items, Celgene earned $1.29 per share.